Sonire Therapeutics, a pancreatic cancer treatment device developer, raised an $18 million Series A, CEO Tohru Satoh exclusively tells Axios Pro.
Why it matters: The company says early data indicates the device can delay the progression of pancreatic cancer — one of the deadliest cancers, with few effective treatments.
